lidocaine has been researched along with Abdominal Migraine in 65 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Four-weekly greater occipital nerve blockade with 2% lidocaine for 12 weeks was superior to placebo in decreasing the average number of headache and migraine days in patients with chronic migraine with a good tolerability profile." | 5.69 | Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study. ( Chowdhury, D; Deorari, V; Duggal, A; Koul, A; Krishnan, A; Tomar, A, 2023) |
| "This study showed that GONB with lidocaine can improve sleep quality, insomnia, and symptoms of depression and anxiety while reducing migraine headache." | 4.31 | The effects of greater occipital nerve blockage with lidocaine on sleep characteristics in chronic migraine patients. ( Dilek, SS; İnan, LE; Karaduman, Y; Metin, KM; Serçe, A; Takmaz, SA, 2023) |
| "A hundred patients with migraine attacks, aged between 18 and 65, were randomly divided into two groups." | 3.11 | Intravenous lidocaine vs. NSAIDs for migraine attack in the ED: a prospective, randomized, double-blind study. ( Ahiskalioglu, A; Ahiskalioglu, EO; Aydin, ME; Aydin, P; Gur, STA; Kocak, AO, 2022) |
| "Status migrainosus is a disabling complication of migraine, which frequently results in hospitalisation." | 3.11 | Status migrainosus inpatient treatment with eptinezumab (SMITE): study protocol for a randomised controlled trial. ( Chen, Z; Germaine, J; Hutton, EJ; Ramsay, G; Ray, JC, 2022) |
| "Eighty-seven patients diagnosed with migraine without aura were included in the study." | 2.90 | Greater occipital and supraorbital nerve blockade for the preventive treatment of migraine: a single-blind, randomized, placebo-controlled study. ( Altun, D; Bölük, C; Köseoğlu Toksoy, C; Özer, D; Taşdemir, M; Türk Börü, Ü, 2019) |
| "Migraine affects more than 35 million people in the United States of America, and 10% of the population in the world." | 2.87 | Effectiveness of surgical treatment in chronic migraine. ( Amaya-Blas, FJ; Castro-Góvea, Y; Chacón-Moreno, H; Coutiño, R; García-Pérez, MM; Marfil-Rivera, A; Mecott, GA; Pérez-Porras, S; Tamayo-Esquivel, ML, 2018) |
| "Included patients met the migraine criteria of the International Headache Society." | 2.84 | Intranasal Lidocaine in Acute Treatment of Migraine: A Randomized Controlled Trial. ( Akalın, LE; Alyeşil, C; Avcu, N; Doğan, NÖ; Pekdemir, M; Yaka, E; Yılmaz, S, 2017) |
| " The most frequently reported adverse events in both groups were associated with nasal discomfort." | 2.77 | Intranasal ketorolac tromethamine (SPRIX(R)) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial. ( Bregman, D; Färkkila, M; Fenzl, E; Pfaffenrath, V, 2012) |
| "Many patients with refractory chronic migraine have experienced treatment failure with the Raskin protocol." | 2.72 | Beyond the Raskin Protocol: Ketamine, Lidocaine, and Other Therapies for Refractory Chronic Migraine. ( Lauritsen, C; Mojica, JJ; Nahas, SJ; Schwenk, ES, 2021) |
| "Subjects scored the intensity of headache and nausea on separate visual analogue scales before the injection and at 10 and 20 min after injection." | 2.67 | Is intravenous lidocaine clinically effective in acute migraine? ( Fatovich, DM; Prentice, DA; Reutens, DC; Stewart-Wynne, EG, 1991) |
| "Pediatric migraine is a common, chronic, and disabling neurological disorder in children and adolescents." | 2.66 | Intravenous Migraine Treatment in Children and Adolescents. ( Hershey, AD; Kabbouche, M; Maconochie, I; Murphy, B; Qaiser, S; Werner, K, 2020) |
| "While 21 out of 39 episodic migraine (EM) patients continued to use prophylactic medications, 18 were followed up with PNB alone." | 1.91 | Evaluation of the efficacy of peripheral nerve block alone in episodic and chronic migraine patients. ( Evcili, G; Yabalak, A, 2023) |
| "Patients with refractory chronic migraine have poor quality of life." | 1.72 | Lidocaine infusions for refractory chronic migraine: a retrospective analysis. ( Lauritsen, CG; Mukhtar, S; Nardone, B; Patel, HT; Schwenk, ES; Silberstein, SD; Sun, G; Thota, B; Torjman, MC; Walter, A, 2022) |
| "Patients with refractory chronic migraine have substantial disability and have failed many acute and preventive medications." | 1.62 | Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis. ( Denk, W; Katz, D; Lauritsen, C; Lovett, J; Moaddel, R; Schwenk, ES; Silberstein, SD; Torjman, MC; Wainer, IW, 2021) |
| "In two patients with status migrainosus, migraine-related disability 3 months prior and after treatment using MIDAS (Migraine Disability Assessment) questionnaire was recorded." | 1.62 | Intra-arterial injection of lidocaine into middle meningeal artery to treat intractable headaches and severe migraine. ( Babar, S; French, BR; Gomez, CR; Huang, W; Ishfaq, MF; Lobanova, I; Pfeiffer, K; Qureshi, AI; Siddiq, F, 2021) |
| "The outcomes observed were migraine pain before and after administration within the same initial encounter of receiving an occipital nerve block using a numeric pain rating scale, injection direction, medications used, duration of effect and frequency of additional injections, and adverse reactions." | 1.56 | Evaluation of Occipital Nerve Blocks for Acute Pain Relief of Migraines. ( Dang, T; Ebied, AM; Nguyen, DT, 2020) |
| "Although migraine is one of the most common primary headaches, its therapy is still limited in many cases." | 1.56 | Trigeminal activation patterns evoked by chemical stimulation of the dura mater in rats. ( Bohár, Z; Fejes-Szabó, A; Laborc, KF; Nagy-Grócz, G; Párdutz, Á; Spekker, E; Szűcs, M; Vécsei, L, 2020) |
| "A sudden loss of consciousness and tonic-clonic seizure was occurred after negative aspiration and test dose." | 1.51 | Tonic-clonic seizure during the ultrasound-guided stellate ganglion block because of an injection into an unrecognized variant vertebral artery: A case report. ( Dong, J; Lu, F; Tian, J; Zhang, K, 2019) |
| "Lidocaine was administered as a bolus (2." | 1.48 | Safety and Efficacy of IV Lidocaine in the Treatment of Children and Adolescents With Status Migraine. ( Ayulo, MA; Phillips, KE; Tripathi, S, 2018) |
| "Therapeutic management of Chronic Migraine (CM), often associated with Medication Overuse Headache (MOH), is chiefly empirical, as no biomarker predicting or correlating with clinical efficacy is available to address therapeutic choices." | 1.48 | Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology. ( Altieri, M; Di Piero, V; Petolicchio, B; Puledda, F; Ruggiero, S; Sasso D'Elia, T; Schoenen, J; Torrieri, MC; Toscano, M; Verzina, A; Vicenzini, E; Viganò, A, 2018) |
| "Thus the pain of migraine may not always be the result of peripheral sensory stimulation, but may also arise by a central mechanism." | 1.37 | Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system. ( Lambert, GA; Truong, L; Zagami, AS, 2011) |
| "The pathophysiology of many types of chronic headaches is not well understood." | 1.33 | Cervicogenic headache in patients with presumed migraine: missed diagnosis or misdiagnosis? ( Cook, AJ; Hamill-Ruth, RJ; Rowlingson, JC; Yi, X, 2005) |
| "Five infusions were given for status migrainosus in three patients, with four of these infusions successfully relieving the headache." | 1.31 | Intravenous lignocaine infusions for severe chronic daily headache. ( Hand, PJ; Stark, RJ, 2000) |
| "In a noncontrolled study, 23 migraine headache patients were treated with intranasal instillation of 0." | 1.29 | Rapid and sustained relief of migraine attacks with intranasal lidocaine: preliminary findings. ( Kudrow, DB; Kudrow, L; Sandweiss, JH, 1995) |
| "Sumatriptan was not used in patients with chronic daily headaches; in the 8 cases of acute migraine or status migrainosus in which it was used, improvement was rapid and complete in seven." | 1.28 | The hospital management of severe migrainous headache. ( Goadsby, PJ; Jauslin, P; Lance, JW, 1991) |
| "In many patients with migraine, several localised areas usually on the scalp or neck can be identified." | 1.26 | The treatment of pain trigger areas in migraine. ( Hay, KM, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (12.31) | 18.7374 |
| 1990's | 17 (26.15) | 18.2507 |
| 2000's | 6 (9.23) | 29.6817 |
| 2010's | 19 (29.23) | 24.3611 |
| 2020's | 15 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Gur, STA | 1 |
| Ahiskalioglu, EO | 1 |
| Aydin, ME | 1 |
| Kocak, AO | 1 |
| Aydin, P | 1 |
| Ahiskalioglu, A | 1 |
| Malekian, N | 1 |
| Bastani, PB | 1 |
| Oveisgharan, S | 1 |
| Nabaei, G | 1 |
| Abdi, S | 1 |
| Mojica, JJ | 1 |
| Schwenk, ES | 3 |
| Lauritsen, C | 2 |
| Nahas, SJ | 1 |
| Chowdhury, D | 2 |
| Mundra, A | 1 |
| Datta, D | 1 |
| Duggal, A | 2 |
| Krishnan, A | 2 |
| Koul, A | 2 |
| Ray, JC | 1 |
| Chen, Z | 1 |
| Ramsay, G | 1 |
| Germaine, J | 1 |
| Hutton, EJ | 1 |
| Walter, A | 1 |
| Torjman, MC | 2 |
| Mukhtar, S | 1 |
| Patel, HT | 1 |
| Nardone, B | 1 |
| Sun, G | 1 |
| Thota, B | 1 |
| Lauritsen, CG | 1 |
| Silberstein, SD | 3 |
| Tomar, A | 1 |
| Deorari, V | 1 |
| Metin, KM | 1 |
| Dilek, SS | 1 |
| Karaduman, Y | 1 |
| Serçe, A | 1 |
| Takmaz, SA | 1 |
| İnan, LE | 1 |
| Evcili, G | 1 |
| Yabalak, A | 1 |
| Ebied, AM | 1 |
| Nguyen, DT | 1 |
| Dang, T | 1 |
| Chi, PW | 2 |
| Hsieh, KY | 2 |
| Chen, KY | 1 |
| Hsu, CW | 2 |
| Bai, CH | 2 |
| Chen, C | 2 |
| Hsu, YP | 2 |
| Lu, F | 1 |
| Tian, J | 1 |
| Dong, J | 1 |
| Zhang, K | 1 |
| Werner, K | 1 |
| Qaiser, S | 1 |
| Kabbouche, M | 1 |
| Murphy, B | 1 |
| Maconochie, I | 1 |
| Hershey, AD | 1 |
| Laborc, KF | 1 |
| Spekker, E | 1 |
| Bohár, Z | 1 |
| Szűcs, M | 1 |
| Nagy-Grócz, G | 1 |
| Fejes-Szabó, A | 1 |
| Vécsei, L | 1 |
| Párdutz, Á | 1 |
| Moaddel, R | 1 |
| Lovett, J | 1 |
| Katz, D | 1 |
| Denk, W | 1 |
| Wainer, IW | 1 |
| Hokenek, NM | 1 |
| Ozer, D | 2 |
| Yılmaz, E | 1 |
| Baskaya, N | 1 |
| Hokenek, UD | 1 |
| Ak, R | 1 |
| Guven, R | 1 |
| Erdogan, MO | 1 |
| Mepham, LA | 1 |
| Qureshi, AI | 1 |
| Pfeiffer, K | 1 |
| Babar, S | 1 |
| Huang, W | 1 |
| Lobanova, I | 1 |
| Ishfaq, MF | 1 |
| French, BR | 1 |
| Siddiq, F | 1 |
| Gomez, CR | 1 |
| Çatav, S | 1 |
| Alkaya Solmaz, F | 1 |
| Kırdemir, P | 1 |
| Levin, D | 1 |
| Cohen, S | 1 |
| Mellender, S | 1 |
| Kiss, G | 1 |
| Amaya-Blas, FJ | 1 |
| Mecott, GA | 1 |
| Marfil-Rivera, A | 1 |
| Tamayo-Esquivel, ML | 1 |
| García-Pérez, MM | 1 |
| Chacón-Moreno, H | 1 |
| Pérez-Porras, S | 1 |
| Coutiño, R | 1 |
| Castro-Góvea, Y | 1 |
| Ayulo, MA | 1 |
| Phillips, KE | 1 |
| Tripathi, S | 1 |
| Tasker, RC | 1 |
| Viganò, A | 1 |
| Torrieri, MC | 1 |
| Toscano, M | 1 |
| Puledda, F | 1 |
| Petolicchio, B | 1 |
| Sasso D'Elia, T | 1 |
| Verzina, A | 1 |
| Ruggiero, S | 1 |
| Altieri, M | 1 |
| Vicenzini, E | 1 |
| Schoenen, J | 1 |
| Di Piero, V | 1 |
| Bölük, C | 1 |
| Türk Börü, Ü | 1 |
| Altun, D | 1 |
| Taşdemir, M | 1 |
| Köseoğlu Toksoy, C | 1 |
| Vanderpol, J | 1 |
| Jonker, L | 1 |
| Tsai, CW | 1 |
| Ilhan Alp, S | 1 |
| Alp, R | 1 |
| Kashipazha, D | 1 |
| Nakhostin-Mortazavi, A | 1 |
| Mohammadianinejad, SE | 1 |
| Bahadoram, M | 1 |
| Zandifar, S | 1 |
| Tarahomi, S | 1 |
| Dilli, E | 1 |
| Halker, R | 1 |
| Vargas, B | 1 |
| Hentz, J | 1 |
| Radam, T | 1 |
| Rogers, R | 1 |
| Dodick, D | 1 |
| Cohen, SP | 1 |
| Peterlin, BL | 1 |
| Fulton, L | 1 |
| Neely, ET | 1 |
| Kurihara, C | 1 |
| Gupta, A | 1 |
| Mali, J | 1 |
| Fu, DC | 1 |
| Jacobs, MB | 1 |
| Plunkett, AR | 1 |
| Verdun, AJ | 1 |
| Stojanovic, MP | 1 |
| Hanling, S | 1 |
| Constantinescu, O | 1 |
| White, RL | 1 |
| McLean, BC | 1 |
| Pasquina, PF | 1 |
| Zhao, Z | 1 |
| Avcu, N | 1 |
| Doğan, NÖ | 1 |
| Pekdemir, M | 1 |
| Yaka, E | 1 |
| Yılmaz, S | 1 |
| Alyeşil, C | 1 |
| Akalın, LE | 1 |
| Saracco, MG | 1 |
| Valfrè, W | 1 |
| Cavallini, M | 1 |
| Aguggia, M | 1 |
| Lambert, GA | 1 |
| Truong, L | 1 |
| Zagami, AS | 1 |
| Pfaffenrath, V | 1 |
| Fenzl, E | 1 |
| Bregman, D | 1 |
| Färkkila, M | 1 |
| Dimitriou, V | 1 |
| Iatrou, C | 1 |
| Malefaki, A | 1 |
| Pratsas, C | 1 |
| Simopoulos, C | 1 |
| Voyagis, GS | 1 |
| DESCOMPS, H | 1 |
| Amparán-Estrada, S | 1 |
| Yi, X | 1 |
| Cook, AJ | 1 |
| Hamill-Ruth, RJ | 1 |
| Rowlingson, JC | 1 |
| Ashkenazi, A | 1 |
| Matro, R | 1 |
| Shaw, JW | 1 |
| Abbas, MA | 1 |
| Tfelt-Hansen, P | 1 |
| Olesen, J | 1 |
| Lous, I | 1 |
| Maxwell, RE | 1 |
| Kudrow, L | 1 |
| Kudrow, DB | 1 |
| Sandweiss, JH | 1 |
| Kaube, H | 1 |
| Goadsby, PJ | 2 |
| Diamond, ML | 1 |
| Lane, RJ | 1 |
| Sachs, CJ | 1 |
| Tulchinsky, A | 1 |
| Burstein, R | 1 |
| Yamamura, H | 1 |
| Malick, A | 1 |
| Strassman, AM | 1 |
| Hand, PJ | 1 |
| Stark, RJ | 1 |
| Buckley, R | 1 |
| McCurry, T | 1 |
| Gera, J | 1 |
| Maizels, M | 2 |
| Geiger, AM | 1 |
| Hay, KM | 1 |
| Rothbart, P | 1 |
| Lewis, GB | 1 |
| Jauslin, P | 1 |
| Lance, JW | 1 |
| Reutens, DC | 1 |
| Fatovich, DM | 1 |
| Stewart-Wynne, EG | 1 |
| Prentice, DA | 1 |
| Keil, G | 1 |
| Taubert, K | 1 |
| Bell, R | 1 |
| Montoya, D | 1 |
| Shuaib, A | 1 |
| Lee, MA | 1 |
| Shute, WB | 1 |
| Burke, M | 2 |
| Barker, PG | 1 |
| Blumenthal, LS | 1 |
| Maritano, M | 1 |
| Marchisio, O | 1 |
| Ghilardi, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy of Intravenous Lidocaine Infusion in Chronic Unilateral Migraine Headache Clinical and Laboratory Assessment .Aprospective Randomized Double Blind Controlled Study[NCT06109389] | Phase 2 | 80 participants (Actual) | Interventional | 2023-10-01 | Active, not recruiting | ||
| Comparison of Great Occipital Nerve and Supraorbital Nerve Blockade Treatment Methods Individually and in Combination With Placebo in an Acute Migraine Attack in the Emergency Department, a Prospective, Double Blind, Randomized Controlled Study[NCT04491474] | Phase 4 | 128 participants (Actual) | Interventional | 2020-08-15 | Completed | ||
| Greater Occipital Nerve Block for Migraine Prophylaxis[NCT00915473] | Phase 4 | 70 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Comparison of Heated vs. Pulsed Radiofrequency Treatment of the Genicular Nerves for Osteoarthritis Knee Pain[NCT04379895] | 60 participants (Anticipated) | Interventional | 2020-06-30 | Not yet recruiting | |||
| A Comparison of Pain Control AND Quality of Life Improvement Between Occipital Nerve Block And Occipital Nerve Radiofrequency Ablation: A Double-Blind Single Center Prospective Study[NCT04124458] | 70 participants (Anticipated) | Interventional | 2023-01-02 | Not yet recruiting | |||
| Pulsed vs Continuous Radiofrequency Neurotomy for Cervical Facet Joint Mediated Pain: a Single-blind Randomized Controlled Clinical Trial[NCT04124445] | 88 participants (Anticipated) | Interventional | 2020-02-10 | Recruiting | |||
| Randomized, Double-blind, Comparative-effectiveness Study Comparing Corticosteroid Injections to Pulsed Radiofrequency for Occipital Neuralgia[NCT01670825] | 81 participants (Actual) | Interventional | 2012-08-31 | Completed | |||
| Greater Occipital Nerve Pulsed Radiofrequency for the Treatment of Combined Migraine and Cervicogenic Headache (New Approach): Randomized Clinical Trial[NCT06121037] | 60 participants (Actual) | Interventional | 2022-01-01 | Completed | |||
| Sphenopalatine Ganglion Blocks for Headaches in the Emergency Department[NCT04255420] | Phase 4 | 84 participants (Anticipated) | Interventional | 2020-02-21 | Recruiting | ||
| A Prospective, Open-label, Nonrandomized Efficacy and Safety Trial of Intranasal Ketorolac in Emergency Department Patients for the Treatment of Acute Pain[NCT01471639] | 37 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department[NCT03576820] | Phase 3 | 50 participants (Anticipated) | Interventional | 2018-10-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Acute medication use meant the consumption of a drug to abort or terminate a headache." (NCT00915473)
Timeframe: 4 weeks post-injection
| Intervention | days per 4 weeks (Mean) |
|---|---|
| Active Injection | 6.7 |
| Placebo Injection | 7.7 |
(NCT00915473)
Timeframe: 4 weeks post-injection
| Intervention | hours per 4 weeks (Mean) |
|---|---|
| Active Injection | 60 |
| Placebo Injection | 58 |
The baseline frequency will be the number of calendar days with moderate or severe migraine during the 4 week period prior to injection, and the follow-up frequency will be the number of calendar days with migraine during the 4 week period following injection. (NCT00915473)
Timeframe: 4 weeks pre-injection baseline, 4 weeks post-injection
| Intervention | participants (Number) |
|---|---|
| Active Injection | 10 |
| Placebo Injection | 9 |
(NCT00915473)
Timeframe: 4 weeks post-injection
| Intervention | days per 4 weeks (Mean) | ||
|---|---|---|---|
| Severe | At Least Moderate | At Least Mild | |
| Active Injection | 3.4 | 7.0 | 9.3 |
| Placebo Injection | 2.9 | 7.8 | 10.4 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.495 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 3.694 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.791 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.441 |
The change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.312 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.765 |
The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.068 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 3.738 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.392 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.220 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.000 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.694 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.761 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.556 |
This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.678 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.410 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.540 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.650 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.522 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.417 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.761 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.556 |
This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.583 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.825 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 9.539 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 9.069 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 9.256 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 9.431 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 10.025 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 8.132 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 11.333 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 11.972 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 12.590 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 12.250 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 12.775 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 10.842 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.726 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 5.846 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.850 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.149 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.705 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.541 |
The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.354 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.064 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 59.718 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 60.556 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 59.641 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 61.389 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 60.087 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 59.553 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 3 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.087 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.263 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.044 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.368 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.708 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.810 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: 3 months
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.846 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.919 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.128 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.162 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.436 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.436 |
Change in numeric rating scale after receiving intranasal ketorolac. 0 (no pain) - 10 (worst possible pain) (NCT01471639)
Timeframe: up to 4 hours
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline72130429 | 20 minutes72130429 | 40 minutes72130429 | 1 hour72130429 | 2 hoiurs72130429 | 3 hours72130429 | 4 hours72130429 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reported Pain Score of 10 | Reported Pain Score of 9 | Reported Pain Score of 8 | Reported Pain Score of 7 | Reported Pain Score of 6 | Reported Pain Score of 5 | Reported Pain Score of 4 | REported Pain Score of 3 | Reported Pain Score of 2 | Reported Pain Score of 1 | Reported Pain Score of 0 | No Rating | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 36 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intranasal Ketorolac (Sprix) | 37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 reviews available for lidocaine and Abdominal Migraine
| Article | Year |
|---|---|
Beyond the Raskin Protocol: Ketamine, Lidocaine, and Other Therapies for Refractory Chronic Migraine.
Topics: Analgesics; Humans; Ketamine; Lidocaine; Migraine Disorders; Prospective Studies | 2021 |
Intranasal lidocaine for acute migraine: A meta-analysis of randomized controlled trials.
Topics: Acute Disease; Administration, Intranasal; Humans; Lidocaine; Migraine Disorders; Randomized Control | 2019 |
Intravenous Migraine Treatment in Children and Adolescents.
Topics: Administration, Intravenous; Adolescent; Akathisia, Drug-Induced; Anesthetics, Local; Anti-Inflammat | 2020 |
Intranasal lidocaine for acute migraine: A protocol for the systematic review of randomized clinical trials.
Topics: Acute Disease; Administration, Intranasal; Anesthetics, Local; Humans; Lidocaine; Migraine Disorders | 2019 |
20 trials available for lidocaine and Abdominal Migraine
| Article | Year |
|---|---|
Intravenous lidocaine vs. NSAIDs for migraine attack in the ED: a prospective, randomized, double-blind study.
Topics: Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Hum | 2022 |
Preventive effect of greater occipital nerve block on patients with episodic migraine: A randomized double-blind placebo-controlled clinical trial.
Topics: Adult; Headache; Humans; Iran; Lidocaine; Migraine Disorders; Nerve Block; Triamcinolone | 2022 |
Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial.
Topics: Adult; Double-Blind Method; Fructose; Headache; Humans; Lidocaine; Migraine Disorders; Nerve Block; | 2022 |
Status migrainosus inpatient treatment with eptinezumab (SMITE): study protocol for a randomised controlled trial.
Topics: Antibodies, Monoclonal, Humanized; Double-Blind Method; Hospitalization; Humans; Inpatients; Lidocai | 2022 |
Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study.
Topics: Double-Blind Method; Headache; Humans; Lidocaine; Migraine Disorders; Nerve Block; Treatment Outcome | 2023 |
Comparison of greater occipital nerve and supra orbital nerve blocks methods in the treatment of acute migraine attack: A randomized double-blind controlled trial.
Topics: Adult; Anesthetics, Local; Double-Blind Method; Female; Humans; Lidocaine; Male; Migraine Disorders; | 2021 |
Effectiveness of surgical treatment in chronic migraine.
Topics: Adolescent; Adult; Chronic Disease; Decompression, Surgical; Facial Muscles; Female; Humans; Lidocai | 2018 |
Greater occipital and supraorbital nerve blockade for the preventive treatment of migraine: a single-blind, randomized, placebo-controlled study.
Topics: Adult; Anesthetics, Local; Female; Humans; Lidocaine; Male; Middle Aged; Migraine Disorders; Nerve B | 2019 |
Preventive effect of greater occipital nerve block on severity and frequency of migraine headache.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Anti-Inflammatory Agents; Cranial Nerves; Double-Blind | 2014 |
Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anesthetics, Local; Bupivacaine; Double-Blind Meth | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Intranasal Lidocaine in Acute Treatment of Migraine: A Randomized Controlled Trial.
Topics: Acute Disease; Administration, Intranasal; Adult; Anesthetics, Local; Antiemetics; Double-Blind Meth | 2017 |
Greater occipital nerve block in chronic migraine.
Topics: Anesthetics, Local; Bupivacaine; Humans; Lidocaine; Migraine Disorders; Nerve Block; Peripheral Nerv | 2010 |
Intranasal ketorolac tromethamine (SPRIX(R)) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial.
Topics: Administration, Intranasal; Adolescent; Adult; Anesthetics, Local; Cyclooxygenase Inhibitors; Double | 2012 |
Blockade of branches of the ophthalmic nerve in the management of acute attack of migraine.
Topics: Acute Disease; Adult; Anesthetics, Local; Epinephrine; Female; Humans; Lidocaine; Middle Aged; Migra | 2002 |
Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study.
Topics: Adult; Anesthetics, Local; Anti-Inflammatory Agents; Bupivacaine; Cranial Nerves; Drug Therapy, Comb | 2008 |
Lignocaine versus saline in migraine pain.
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Injections, Intramuscular; Lidocaine; Migrain | 1980 |
Intranasal lidocaine for migraine: a randomized trial and open-label follow-up.
Topics: Administration, Intranasal; Adult; Anesthetics, Local; Double-Blind Method; Female; Follow-Up Studie | 1999 |
Intranasal lidocaine for migraine: a randomized trial and open-label follow-up.
Topics: Administration, Intranasal; Adult; Anesthetics, Local; Double-Blind Method; Female; Follow-Up Studie | 1999 |
Intranasal lidocaine for migraine: a randomized trial and open-label follow-up.
Topics: Administration, Intranasal; Adult; Anesthetics, Local; Double-Blind Method; Female; Follow-Up Studie | 1999 |
Intranasal lidocaine for migraine: a randomized trial and open-label follow-up.
Topics: Administration, Intranasal; Adult; Anesthetics, Local; Double-Blind Method; Female; Follow-Up Studie | 1999 |
Is intravenous lidocaine clinically effective in acute migraine?
Topics: Acute Disease; Adult; Double-Blind Method; Female; Humans; Injections, Intravenous; Lidocaine; Male; | 1991 |
A comparative trial of three agents in the treatment of acute migraine headache.
Topics: Adult; Chlorpromazine; Dihydroergotamine; Emergencies; Follow-Up Studies; Humans; Infusions, Intrave | 1990 |
41 other studies available for lidocaine and Abdominal Migraine
| Article | Year |
|---|---|
Lidocaine infusions for refractory chronic migraine: a retrospective analysis.
Topics: Adult; Aftercare; Female; Headache; Humans; Infusions, Intravenous; Lidocaine; Male; Middle Aged; Mi | 2022 |
The effects of greater occipital nerve blockage with lidocaine on sleep characteristics in chronic migraine patients.
Topics: Adult; Female; Humans; Lidocaine; Middle Aged; Migraine Disorders; Pain; Sleep; Sleep Initiation and | 2023 |
Evaluation of the efficacy of peripheral nerve block alone in episodic and chronic migraine patients.
Topics: Anesthetics, Local; Humans; Lidocaine; Migraine Disorders; Peripheral Nerves; Retrospective Studies; | 2023 |
Evaluation of Occipital Nerve Blocks for Acute Pain Relief of Migraines.
Topics: Acute Pain; Adult; Aged; Anesthetics, Local; Bupivacaine; Dexamethasone; Female; Florida; Glucocorti | 2020 |
Tonic-clonic seizure during the ultrasound-guided stellate ganglion block because of an injection into an unrecognized variant vertebral artery: A case report.
Topics: Adult; Anesthetics, Local; Autonomic Nerve Block; Humans; Intraoperative Complications; Lidocaine; M | 2019 |
Trigeminal activation patterns evoked by chemical stimulation of the dura mater in rats.
Topics: Animals; Dura Mater; Freund's Adjuvant; Headache; Inflammation; Lidocaine; Male; Migraine Disorders; | 2020 |
Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis.
Topics: Adult; Analgesics; Chronic Disease; Female; Humans; Ketamine; Lidocaine; Male; Middle Aged; Migraine | 2021 |
Intra-arterial injection of lidocaine into middle meningeal artery to treat intractable headaches and severe migraine.
Topics: Headache Disorders; Humans; Injections, Intra-Arterial; Lidocaine; Meningeal Arteries; Migraine Diso | 2021 |
[The results of greater occipital nerve block applied for migraine headache].
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Female; Humans; Lidocaine; Male; Middle Aged; Migraine | 2017 |
Sphenopalatine Ganglion Block Successfully Treats Migraines in a Type 1 Arnold Chiari Malformation Pregnant Patient: A Case Report.
Topics: Administration, Intranasal; Adult; Anesthetics, Local; Arnold-Chiari Malformation; Female; Humans; L | 2018 |
Safety and Efficacy of IV Lidocaine in the Treatment of Children and Adolescents With Status Migraine.
Topics: Adolescent; Anesthetics, Local; Child; Female; Humans; Infusions, Intravenous; Intensive Care Units, | 2018 |
IV Lidocaine for Status Migraine: Making an "Off-Label" Treatment Decision.
Topics: Adolescent; Child; Humans; Lidocaine; Migraine Disorders; Off-Label Use | 2018 |
Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology.
Topics: Adolescent; Adult; Anesthetics, Local; Autonomic Nerve Block; Betamethasone; Chronic Disease; Evoked | 2018 |
Influence of patient positioning on reported clinical outcomes after greater occipital nerve block for treatment of headache: Results from prospective single-centre, non-randomised, proof-of-concept study.
Topics: Adult; Anesthesia, Conduction; Anesthetics, Local; Headache; Humans; Lidocaine; Middle Aged; Migrain | 2019 |
Supraorbital and infraorbital nerve blockade in migraine patients: results of 6-month clinical follow-up.
Topics: Adult; Anesthetics, Local; Disability Evaluation; Female; Follow-Up Studies; Humans; Lidocaine; Male | 2013 |
Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system.
Topics: Anesthetics, Local; Animals; Cortical Spreading Depression; Dura Mater; Electric Stimulation; Evoked | 2011 |
[STIMULATION OF HYPOTHALAMO-HYPOPHYSIAL SECRETIONS IN MAN BY RETRO-STYLOID ANESTHETIC INFILTRATION].
Topics: Adrenocorticotropic Hormone; Anesthetics; Asthma; Autonomic Nerve Block; Eczema; Endocrinology; Huma | 1963 |
Management of acute migraine headache with lidocaine.
Topics: Anesthetics, Local; Botulinum Toxins, Type A; Humans; Lidocaine; Migraine Disorders; Neuromuscular A | 2005 |
Cervicogenic headache in patients with presumed migraine: missed diagnosis or misdiagnosis?
Topics: Adult; Aged; Anesthetics, Local; Bupivacaine; Cervical Plexus; Cervical Vertebrae; Chronic Disease; | 2005 |
Surgical control of chronic migrainous neuralgia by trigeminal ganglio-rhizolysis.
Topics: Adult; Chronic Disease; Ergotamine; Humans; Lidocaine; Lithium; Male; Methysergide; Middle Aged; Mig | 1982 |
Rapid and sustained relief of migraine attacks with intranasal lidocaine: preliminary findings.
Topics: Administration, Intranasal; Adult; Clinical Trials as Topic; Female; Humans; Lidocaine; Male; Middle | 1995 |
Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat.
Topics: Analgesics; Animals; Aspirin; Cats; Cerebral Cortex; Clonazepam; Cortical Spreading Depression; Dihy | 1994 |
Intranasal lidocaine for treatment of migraine.
Topics: Acute Disease; Administration, Intranasal; Humans; Lidocaine; Migraine Disorders | 1996 |
Intranasal lidocaine for treatment of migraine.
Topics: Acute Disease; Diagnosis, Differential; Humans; Lidocaine; Migraine Disorders; Tomography, X-Ray Com | 1996 |
Intranasal lidocaine for treatment of migraine.
Topics: Acute Disease; Administration, Intranasal; Humans; Lidocaine; Migraine Disorders | 1996 |
Intranasal lidocaine for treatment of migraine.
Topics: Acute Disease; Administration, Inhalation; Humans; Lidocaine; Migraine Disorders | 1996 |
Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons.
Topics: Anesthetics, Local; Animals; Bradykinin; Brain Stem; Dinoprostone; Dura Mater; Electric Stimulation; | 1998 |
Intravenous lignocaine infusions for severe chronic daily headache.
Topics: Adolescent; Adult; Anesthetics, Local; Chronic Disease; Clinical Protocols; Drug Monitoring; Female; | 2000 |
Intranasal lidocaine for migraine using a metered-dose spray.
Topics: Administration, Intranasal; Anesthetics, Local; Humans; Lidocaine; Migraine Disorders; Nebulizers an | 2000 |
Intranasal lidocaine to prevent headache following migraine aura.
Topics: Administration, Intranasal; Adolescent; Facial Nerve; Humans; Lidocaine; Male; Migraine Disorders; T | 1999 |
The treatment of pain trigger areas in migraine.
Topics: Adult; Epinephrine; Female; Humans; Lidocaine; Male; Middle Aged; Migraine Disorders | 1976 |
Unilateral headache with features of hemicrania continua and cervicogenic headache--a case report.
Topics: Adult; Anti-Inflammatory Agents; Female; Headache; Humans; Injections, Spinal; Lidocaine; Methylpred | 1992 |
Lignocaine suppositories for migraine.
Topics: Adult; Humans; Lidocaine; Migraine Disorders; Suppositories | 1992 |
The hospital management of severe migrainous headache.
Topics: Adolescent; Adult; Aged; Child; Dihydroergotamine; Drug Therapy, Combination; Female; Humans; Indole | 1991 |
[Can reflexotherapy of the pelvis eliminate or improve a migraine?].
Topics: Adolescent; Adult; Child; Combined Modality Therapy; Female; Humans; Lidocaine; Male; Manipulation, | 1991 |
Migraine headache--a long-term approach.
Topics: Adult; Female; Humans; Injections; Lidocaine; Middle Aged; Migraine Disorders; Myofascial Pain Syndr | 1990 |
Intravenous lignocaine.
Topics: Humans; Infusions, Intravenous; Lidocaine; Migraine Disorders | 1990 |
Intravenous lignocaine for migraine headache.
Topics: Aspirin; Humans; Injections, Intravenous; Lidocaine; Metoclopramide; Migraine Disorders | 1989 |
Treatment for migraine.
Topics: Humans; Lidocaine; Migraine Disorders | 1986 |
Injury to the cervical spine as a cause of headache.
Topics: Adolescent; Female; Head; Headache; Humans; Lidocaine; Male; Middle Aged; Migraine Disorders; Palpat | 1974 |
[Atypical neurovascular pains in the head. Relation between sphygmographic charges caused by anesthetic block and the antalgic effect].
Topics: Adult; Aged; Anesthesia, Conduction; Cerebrovascular Circulation; Epinephrine; Facial Neuralgia; Fem | 1967 |